Related Experiment Videos
Metastatic uveal melanoma.
Arun D Singh1, Ernest C Borden
1Department of Ophthalmic Oncology, Cole Eye Institute, Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195, USA. singha@ccf.org
Ophthalmology Clinics of North America
|March 15, 2005
Summary
Mortality from uveal melanoma, a rare eye cancer, has not improved in the US despite accurate diagnosis. Survival remains poor for patients with metastatic uveal melanoma.
Area of Science:
- Ophthalmology
- Oncology
- Cancer Research
Background:
- Uveal melanoma is the most common primary intraocular malignancy in adults.
- Despite advances in diagnostic accuracy for uveal melanoma in the United States, patient outcomes have not significantly improved.
- There is a critical need to understand the factors contributing to persistent mortality rates.
Purpose of the Study:
- To analyze trends in mortality for uveal melanoma in the United States.
- To evaluate the impact of diagnostic accuracy on patient survival.
- To highlight the poor prognosis associated with metastatic uveal melanoma.
Main Methods:
- Retrospective analysis of uveal melanoma patient data.
- Examination of mortality statistics over a 25-year period (1973-1997).
- Review of survival rates for both primary and metastatic uveal melanoma.
Main Results:
- Mortality rates for uveal melanoma showed no significant change between 1973 and 1997.
- Diagnostic accuracy for uveal melanoma improved during this period.
- Median survival for patients with metastatic uveal melanoma was less than 6 months.
Conclusions:
- Improved diagnostic accuracy for uveal melanoma has not translated into reduced mortality.
- Metastatic uveal melanoma carries a very poor prognosis, underscoring the need for effective systemic therapies.
- Further research is required to identify novel therapeutic strategies to improve survival rates for uveal melanoma patients.